S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
The biology of chronic myeloid leukemia
TL;DR: Although heterogeneous, CML is the best-characterized leukemia at a molecular level, and studies in recent years have helped to define further.
Journal ArticleDOI
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating,Susan O'Brien,Maher Albitar,Susan Lerner,William Plunkett,Francis J. Giles,Michael Andreeff,Jorge E. Cortes,Stefan Faderl,Deborah A. Thomas,Charles Koller,William G. Wierda,Michelle A. Detry,Alice Lynn,Hagop M. Kantarjian +14 more
TL;DR: FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
Journal ArticleDOI
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian,Xavier Thomas,Anna Dmoszynska,Agnieszka Wierzbowska,Grzegorz Mazur,Jiri Mayer,Jyh Pyng Gau,Wen-Chien Chou,Rena Buckstein,Jaroslav Cermak,Ching Yuan Kuo,Albert Oriol,Farhad Ravandi,Stefan Faderl,Jacques Delaunay,Daniel Lysák,Mark D. Minden,Christopher Arthur +17 more
TL;DR: In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety, and an unplanned survival analysis showed a benefit for decit abine, which was not observed at the time of the primary analysis.
Journal ArticleDOI
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Jean Pierre J. Issa,Guillermo Garcia-Manero,Francis J. Giles,Rajan Mannari,Deborah A. Thomas,Stefan Faderl,Emel Bayar,John Lyons,Craig S. Rosenfeld,Jorge E. Cortes,Hagop M. Kantarjian +10 more
TL;DR: It is concluded that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.
Journal ArticleDOI
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop M. Kantarjian,Yasuhiro Oki,Guillermo Garcia-Manero,Xuelin Huang,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,Carlos E. Bueso-Ramos,Farhad Ravandi,Zeev Estrov,Alessandra Ferrajoli,William G. Wierda,Jianqin Shan,Jan Davis,Francis J. Giles,Hussain I. Saba,Jean Pierre J. Issa +16 more
TL;DR: It is concluded that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.